Drug survival rates for tumour necrosis factor- α Antagonists in psoriasis

British Journal of Dermatology

Volumn 164, Issue 5, 2011, Pages 940-941

  Burden, A D ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

HEART INFARCTION; INFLAMMATORY DISEASE; NOTE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; WORK DISABILITY;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; DRUG TOLERANCE; HUMANS; PSORIASIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955439686     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10355.x     Document Type: Note

References (8)

1. Galloway JB, Hyrich KL, Mercer LK, et al; BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011; 50: 124-31.
2. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 583-9.
3. Hyrich KL, Watson KD, Silman AJ, Symmons D,. Predictors of response to anti-TNFα therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006; 45: 1558-65. (Pubitemid 44817065)
4. Verstappen SM, Watson KD, Lunt M, et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2010; 49: 1570-7.
5. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12. (Pubitemid 47502736)
6. Gniadecki R, Kragballe T, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
7. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
8. Woolf RT, Smith CH, Robertson K, Barker JNWN,. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol 2010; 163: 889-91.